Rapid improvement following anti-TNF treatment at the INR is seen. The patient is able to recognize his wife for the first time in years within minutes after treatment. Also seen is his improvement in verbal abilities following the local etanercept dose.

Individual results may vary. Continuing maintenance treatment is necessary to maintain the clinical response. Some patients do not respond. For further scientific information, please see:

• TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. Edward Tobinick MD, H Gross MD, Alan Weinberger MD, Hart Cohen MD. MedGenMed. 2006 Apr 26;8(2):25.
• Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. Edward Tobinick MD, H Gross MD. BMC Neurology. 2008 Jul 21;8:27.
• Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration.Edward Tobinick MD, H Gross MD. Journal of Neuroinflammation. 2008 Jan 9;5:2.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Son comments on the immediate difference he saw after the first dose of his father’s anti-TNF treatment. This video documents the unprecendented rapid improvement that may occur after initiation of treatment at the INR. Includes video both before and after treatment and discussion by the patient’s wife and son.

Individual results may vary. Continuing maintenance treatment is necessary to maintain the clinical response. Some patients do not respond. For further scientific information, please see:

• Perispinal etanercept: a new therapeutic paradigm in neurology. Edward Tobinick MD. Expert Review of Neurotherapeutics. 2010 Jun;10(6):985-1002.
• TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. Edward Tobinick MD, H Gross MD, Alan Weinberger MD, Hart Cohen MD. MedGenMed. 2006 Apr 26;8(2):25.
• Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. Edward Tobinick MD, H Gross MD. BMC Neurology. 2008 Jul 21;8:27.
• Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration.Edward Tobinick MD, H Gross MD. Journal of Neuroinflammation. 2008 Jan 9;5:2.

• Intrathecal inflammation precedes development of Alzheimer’s disease. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1200-5.
• Perispinal etanercept: potential as an Alzheimer therapeutic.Griffin WS. J Neuroinflammation. 2008 Jan 10;5:3.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

A patient with chronic traumatic brain injury discusses his rapid clinical improvement following treatment at the INR in Los Angeles 45 years after  being struck by a car at age 6. This treatment is available for new patients at the INR. For further information, please call the INR in Los Angeles at (310) 479-0107 or at (561) 353-9707 in Boca Raton, Florida.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by the INR, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Find out what the 60 Minutes Australia news team saw and heard when they visited the INR to investigate the patented INR Alzheimer’s treatment program. The patient and her granddaughter describe in detail her rapid and sustained favorable response. Filmed at the INR in 2010.

Individual results may vary. Some patients do not respond. For further scientific information, please see:

• TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. Edward Tobinick MD, H Gross MD, Alan Weinberger MD, Hart Cohen MD. MedGenMed. 2006 Apr 26;8(2):25.
• Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. Edward Tobinick MD, H Gross MD. Journal of Neuroinflammation. 2008 Jan 9;5:2.
• Perispinal etanercept: a new therapeutic paradigm in neurology. Edward Tobinick MD. Expert Review of Neurotherapeutics. 2010 Jun;10(6):985-1002.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Husband and wife discuss improvements following local anti-TNF treatment at the INR in Los Angeles years after stroke. This new patented treatment is available for new patients at the INR. For further information, please call the INR in Los Angeles at (310) 479-0107. The patented INR stroke treatment is also available at the INR PLLC in Boca Raton, Florida; please call (561) 353-9707.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by the INR, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by the INR, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

 

A severe stroke occurred at age 22. Treatment at the INR PLLC in Boca Raton, Florida occurred in September 2011. This video documents some of the clinical improvements noted. This new patented treatment is available for new patients at the INR. For further information, please call the INR in Los Angeles at (310) 479-0107, or in Boca Raton, Florida, at (561) 353-9707.

Please see Rapid improvement of chronic stroke deficits…: three consecutive cases. Edward Tobinick MD. CNS Drugs. 2011 Feb;25(2):145-155.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

In this interview, the son of an INR patient discusses his father’s response since starting treatment at the INR®. He explains how much this has meant to him and his family, and why he and his father have continued to fly to the INR each week for more than one year.

Individual results may vary. Continuing maintenance treatment is necessary to maintain the clinical response. Some patients do not respond. For further scientific information, please see:

• Perispinal etanercept: a new therapeutic paradigm in neurology. Edward Tobinick MD. Expert Review of Neurotherapeutics. 2010 Jun;10(6):985-1002.
• Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. Edward Tobinick MD, H Gross MD. BMC Neurology. 2008 Jul 21;8:27.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Rapid improvement in post-stroke pain and additional clinical improvements documented following the INR’s patented anti-TNF treatment, 17 years after stroke.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Six months of sustained clinical improvement nearly five years after stroke following the INR’s patented off-label treatment is documented. Improvements in hand and arm function, gait, and walking speed are documented.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by the INR, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.